DelveInsight Business Research, a leading healthcare market research and business consulting firm, reports on a landmark regulatory development in the rare blood cancer space. On March 2, 2026, Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced that the FDA has formally accepted the New Drug Application (NDA) for Rusfertide and granted it Priority Review. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of 2026.
Access DelveInsight’s Polycythemia Vera Market Report. Explore the Polycythemia Vera Competitive Landscape, Pipeline, & Forecasts.
About Rusfertide: A First-in-Class Mechanism
Rusfertide is a first-in-class investigational subcutaneous peptide therapeutic that mimics the action of hepcidin, a natural hormone responsible for regulating iron homeostasis and red blood cell (RBC) production. By targeting the ferroportin pathway, the underlying mechanism of iron dysregulation in polycythemia vera, Rusfertide aims to suppress excess erythrocytosis and help patients achieve sustained hematocrit control below the clinically critical threshold of 45%.
Unlike existing cytoreductive therapies such as hydroxyurea, pegylated interferon alfa, or ruxolitinib (Jakafi), Rusfertide operates through an entirely distinct biological axis. No other hepcidin mimetic has previously reached the NDA stage in any indication, making Rusfertide’s regulatory milestone particularly significant.
In addition to Priority Review, Rusfertide has accumulated a notable portfolio of FDA designations: Breakthrough Therapy, Orphan Drug, and Fast Track, each reflecting the FDA’s recognition of the urgent unmet need that persists in the PV space.
Clinical Evidence Behind the Rusfertide NDA Submission
The NDA submission was primarily supported by data from the Phase 3 VERIFY study (NCT05210790), a global, randomized, placebo-controlled trial enrolling 293 patients with polycythemia vera. Results presented at the 2025 American Society of Hematology (ASH) Annual Meeting showed that 76.9% of patients receiving Rusfertide plus standard of care (SOC) achieved a clinical response during weeks 20–32, compared with just 32.9% in the placebo-plus-SOC arm (P < .0001), more than doubling the response rate.
Key secondary endpoints were equally compelling. The mean number of phlebotomies from baseline to week 32 was 0.5 in the Rusfertide group versus 1.8 in the placebo group (P < .0001). Furthermore, 62.6% of Rusfertide-treated patients maintained hematocrit below 45% compared with only 14.4% in the control arm (P < .0001). Patient-reported outcomes also favored Rusfertide, with statistically significant improvements in both PROMIS Fatigue and Myelofibrosis Symptom Assessment Form scores at week 32.
Longer-term data reinforced these findings. At 52 weeks, 84.1% of initial Rusfertide responders maintained their responses, and patients who crossed over from placebo to Rusfertide in Part 1b achieved a 77.9% response rate. The NDA also draws on four-year efficacy and safety data from the Phase 2 REVIVE study and its long-term extension, THRIVE, providing regulators with one of the most comprehensive datasets assembled for a PV therapy to date.
The safety profile was generally manageable. Treatment-emergent adverse events (TEAEs) over 52 weeks included injection site reactions (47.4%), anemia (25.6%), and fatigue (19.6%), the vast majority of which were Grade 1 or 2. Serious adverse events occurred in 8.1% of Rusfertide-treated patients.
Want the Full PV Pipeline & Market Analysis? Download DelveInsight’s Comprehensive Polycythemia Vera Report
Impact on the Polycythemia Vera Treatment Landscape
Polycythemia vera is a rare myeloproliferative neoplasm (MPN) driven predominantly by the JAK2 V617F mutation, which causes the bone marrow to overproduce red blood cells, leading to hyperviscosity, elevated thrombotic risk, and debilitating symptom burden. The primary treatment goal, maintaining hematocrit below 45%, is currently managed through a combination of therapeutic phlebotomy, aspirin, and cytoreductive agents. Despite these options, many patients continue to face inadequate hematocrit control, frequent phlebotomies, drug-related side effects, and significant quality-of-life impairment.
The FDA’s acceptance of Rusfertide’s NDA signals that a fundamentally new treatment modality may soon enter the standard-of-care paradigm. Several dimensions of the treatment landscape stand to be meaningfully disrupted:
-
The phlebotomy burden, a defining and burdensome feature of PV management, could be dramatically reduced. Rusfertide’s ability to limit RBC production through iron regulation means that many patients may no longer require the frequent, invasive blood draws that currently punctuate their care.
-
Rusfertide introduces a new mechanistic category to the PV formulary. While JAK inhibition via ruxolitinib remains the primary targeted therapy in this space, hepcidin mimesis addresses erythrocytosis more directly and specifically, potentially offering advantages in patients who are intolerant of or refractory to cytoreductive regimens.
-
with priority regulatory designations including Breakthrough Therapy and Orphan Drug status, Rusfertide’s commercial launch, should approval follow the Q3 2026 PDUFA date, could accelerate payer and prescriber uptake more rapidly than a standard-review drug would.
-
The competitive dynamics among existing agents, hydroxyurea (generic), ropeginterferon alfa-2b (Besremi, PharmaEssentia), and ruxolitinib (Jakafi, Incyte), will be materially affected, particularly in the second-line and high-risk patient segments where Rusfertide’s differentiated profile could command significant market share.
For pharmaceutical companies, investors, payers, and healthcare providers tracking this market, the Rusfertide NDA represents a critical commercial and clinical inflection point. Understanding the full depth of the opportunity requires a granular view of epidemiology, treatment algorithms, competitive positioning, and revenue projections.
Track Polycythemia Vera Market Share, Epidemiology & Revenue Forecasts with Market Intelligence Report from DelveInsight.
DelveInsight’s Coverage of the Polycythemia Vera Market
DelveInsight’s Polycythemia Vera Market Report delivers a 360-degree analytical view of this evolving therapeutic area, giving stakeholders the commercial and clinical intelligence needed to make informed strategic decisions. The report encompasses detailed epidemiological analysis across the 7MM (United States, EU4, United Kingdom, and Japan), historical and forecasted market sizing, current standard-of-care mapping, pipeline surveillance spanning approved and emerging agents, and comprehensive competitive landscape assessments.
In the context of the Rusfertide NDA, the report is an indispensable resource for understanding where this candidate fits within the current treatment algorithm, how it compares mechanistically and clinically to existing options, which patient segments it is most likely to capture, and what its approval could mean for the overall market valuation through 2034.
Whether you are a biopharma executive evaluating competitive threats, an investor assessing commercial potential, a payer developing formulary strategies, or a clinical researcher tracking the evolving PV standard of care, DelveInsight’s research provides the intelligence foundation you need.
Stay Ahead of the Curve in the Polycythemia Vera landscape. Request DelveInsight’s Polycythemia Vera Market Report Now.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services